ADC Therapeutics SA has announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
Carmona will serve on the company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities.
Carmona has over 20 years of leadership, commercial and partnership experience in the pharmaceutical industry, both in the US and internationally.
Ameet Mallik, Chief Executive Officer of ADC Therapeutics, said:
“We warmly welcome Pepe to ADC Therapeutics.
“As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical industry will help drive our corporate objectives and deliver long-term value for shareholders.
“We would like to sincerely thank Jenn Creel for her many contributions to the Company, including building and leading the financial organisation through multiple stages of our evolution.”
Carmona most recently served as CFO of Rubius Therapeutics where he was responsible for all financial functions as well as business development, investor relations, IT and procurement.
Prior to joining Rubius, he was the CFO of Radius Health and Innocoll.
During his 12 years at Novartis, Carmona held financial management positions with increasing responsibilities in various divisions and geographies, including the role of CFO Alcon for Europe, Middle East and Africa.
Carmona currently serves on the board of directors of HotSpot Therapeutics and Senda Biosciences.
He said:
“I am thrilled to join ADC Therapeutics, especially at this exciting point in the Company’s evolution.
“I believe the Company possesses great potential with its industry-leading expertise and a robust pipeline of innovative assets.
“I welcome the opportunity to collaborate with my new colleagues and contribute to our mission of delivering transformative treatment options to people with cancer.”
